Moreover, multi-omics data has demonstrated significant efficacy of ALK-targeted drugs (such as crizotinib) in ALK-positive lung cancer patients, improving overall survival [199], highlighting the powerful role of multi-omics strategies in precision therapy for patients with lung cancer. This evidence concerns the gene ALK and lung cancer.